Journal of Pharmaceutical Analysis 12 (2022) 937

Contents lists available at ScienceDirect

Journal of Pharmaceutical Analysis

journal homepage: www.elsevier.com/locate/jpa

Corrigendum

Corrigendum to "The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review" [J. Pharma. Anal. 11 (2021) 265–271]

Leonny Dwi Rizkita, Indwiani Astuti*

Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia

Original statement in Section 3:

3. Host-pathogen interactions in SARS-CoV-2 infection

SARS-CoV-2 shares many of the same characteristics as most coronavirus family viruses, including a pleomorphic or spherical shaped capsid envelope 150–160 nm in size, a polycistronic mRNA with a 5′ cap and 3′ poly-A-tail, and an unsegmented, positive, single-stranded RNA genome (30 kb) [32–34]. SARS-CoV-2 has two large polyproteins, ORF1a and ORF1b; four structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N); and eight accessory proteins: ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8a, ORF8b, and ORF9b.

Corrected statement in Section 3:

3. Host-pathogen interactions in SARS-CoV-2 infection

SARS-CoV-2 shares many of the same characteristics as most coronavirus family viruses, including a pleomorphic or spherical shaped capsid envelope 150–160 nm in size, a polycistronic mRNA with a 5′ cap and 3′ poly-A-tail, and an unsegmented, positive, single-stranded RNA genome (30 kb) [32–34]. SARS-CoV-2 has two large polyproteins, ORF1a and ORF1b; four structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N); and some accessory proteins: ORF3a, ORF6, ORF7a, ORF7b, ORF8, and ORF10.

The authors regret to inform that the statement in our review paper regarding the eight accessory proteins of SARS-CoV-2 were wrong and correction has been made to support the current findings.

The authors would like to apologize for any inconvenience caused.

DOI of original article: https://doi.org/10.1016/j.jpha.2021.03.003.
* Corresponding author.
E-mail address: indwiani@gmail.com (I. Astuti).

https://doi.org/10.1016/j.jpha.2022.11.001